Literature DB >> 11566167

Diagnostic value of serum cystatin C for evaluation of hepatorenal syndrome.

S Demirtaş1, A Bozbaş, A Akbay, Y Yavuz, L Karaca.   

Abstract

BACKGROUND: The evaluation of renal function in patients with decompensated cirrhosis is important for prognosis, dosage assessment of potentially nephrotoxic drugs and recognition of changes in glomerular filtration rate (GFR) to decide paracentesis and diuretic therapy. Patients with many different disorders of hepatic function can present with various abnormalities of renal function in the absence of other known causes of renal failure which has been called hepatorenal syndrome (HRS). Some reports have pointed out that serum creatinine levels frequently failed to rise above normal levels even when glomerular filtration rate (GFR) is very low in cirrhotic patients with hepatorenal syndrome. The aim of this study was to determine if estimation of serum cystatin C could replace creatinine clearance in routine GFR determinations for patients with cirrhosis.
METHODS: Serum cystatin C, creatinine clearance (Clcr), and 99mTc-DTPA clearance were determined in 26 patients with cirrhosis. According to Child-Pugh's classification, 21 patients were in group C and 5 were in Group B.
RESULTS: Pearson correlation analyses showed that correlation between serum cystatin C and 99mTc-DTPA clearance was r=-0.522, p=0.006, between serum creatinine and 99mTc-DTPA was r=-0.373, p=0.06. The results of our study demonstrated that neither serum creatinine nor creatinine clearance (Clcr) were good indicators of hepatorenal syndrome because the mean value for Clcr was found to be higher than Tc-DTPA clearance, and there was no correlation between these two parameters (r=0.059). Additionally, the mean value of serum creatinine was found to be within the normal range, whereas the mean DTPA clearance level was lower than normal range.
CONCLUSIONS: This finding could be explained by the fact that cirrhotic patients with poor nutrition may have decreased protein intake, low muscle mass and lack of converting capacity of creatine to creatinine. Thus, we suggest that serum cystatin C assay, which has good analytical performance, could replace or at least be added to creatinine measurement for GFR assessment in patients with cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11566167     DOI: 10.1016/s0009-8981(01)00546-0

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  21 in total

Review 1.  Commentary: clinical diagnostic use of cystatin C.

Authors:  Davis Massey
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

Review 2.  GFR Estimating Equations and Liver Disease.

Authors:  Tomasz Beben; Dena E Rifkin
Journal:  Adv Chronic Kidney Dis       Date:  2015-09       Impact factor: 3.620

3.  Gender disparity in liver transplant waiting-list mortality: the importance of kidney function.

Authors:  Ayse L Mindikoglu; Arie Regev; Stephen L Seliger; Laurence S Magder
Journal:  Liver Transpl       Date:  2010-10       Impact factor: 5.799

4.  Cystatin C is a biomarker for predicting acute kidney injury in patients with acute-on-chronic liver failure.

Authors:  Zhi-Hong Wan; Jian-Jun Wang; Shao-Li You; Hong-Ling Liu; Bing Zhu; Hong Zang; Chen Li; Jing Chen; Shao-Jie Xin
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

5.  Cystatin C: a predictor of hepatorenal syndrome in patients with liver cirrhosis.

Authors:  Mohammed A Sharawey; Eglal M Shawky; Lamia H Ali; Ahmed Ali Mohammed; Hatem A Hassan; Yasser M Fouad
Journal:  Hepatol Int       Date:  2011-03-12       Impact factor: 6.047

Review 6.  Difficulties in diagnosing acute kidney injury post liver transplantation using serum creatinine based diagnostic criteria.

Authors:  Banwari Agarwal; Andrew Davenport
Journal:  World J Hepatol       Date:  2014-10-27

7.  Difference between CKD-EPI and MDRD equations in calculating glomerular filtration rate in patients with cirrhosis.

Authors:  Yu-Wei Chen; Han-Hsiang Chen; Tsang-En Wang; Ching-Wei Chang; Chen-Wang Chang; Chih-Jen Wu
Journal:  World J Gastroenterol       Date:  2011-10-28       Impact factor: 5.742

Review 8.  Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis.

Authors:  Juan Carlos Q Velez; George Therapondos; Luis A Juncos
Journal:  Nat Rev Nephrol       Date:  2019-11-13       Impact factor: 28.314

9.  Cystatin C and creatinine in an HIV cohort: the nutrition for healthy living study.

Authors:  Clara Y Jones; Camille A Jones; Ira B Wilson; Tamsin A Knox; Andrew S Levey; Donna Spiegelman; Sherwood L Gorbach; Frederick Van Lente; Lesley A Stevens
Journal:  Am J Kidney Dis       Date:  2008-05-02       Impact factor: 8.860

10.  Cystatin C--a paradigm of evidence based laboratory medicine.

Authors:  Janice S C Chew; Mohammed Saleem; Christopher M Florkowski; Peter M George
Journal:  Clin Biochem Rev       Date:  2008-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.